#1 Clinical Trials Search in Europe

Fosaprepitant

Fosaprepitant is an intravenous medication being studied in clinical trials for its effectiveness in preventing and treating nausea and vomiting associated with chemotherapy, surgery, and other medical conditions. This article summarizes key findings from recent clinical trials exploring the use of fosaprepitant as an antiemetic drug across various patient populations and clinical scenarios.

Table of Contents

What is Fosaprepitant?

Fosaprepitant is a medication primarily used to prevent nausea and vomiting caused by chemotherapy. It’s also known by its brand names EMEND® for Injection and IVEMEND®[1][2]. Fosaprepitant is a prodrug, which means it’s converted into another active drug in the body called aprepitant[3]. This conversion happens rapidly after the medication is given, making fosaprepitant an effective intravenous (IV) alternative to oral aprepitant.

How Does Fosaprepitant Work?

Fosaprepitant belongs to a class of drugs called NK-1 receptor antagonists. It works by blocking a specific receptor in the brain called neurokinin-1 (NK-1), which is known to cause nausea and vomiting[2]. By blocking this receptor, fosaprepitant helps prevent or reduce the severity of nausea and vomiting, especially in patients undergoing chemotherapy.

Conditions Treated with Fosaprepitant

Fosaprepitant is primarily used to treat and prevent the following conditions:

  • Chemotherapy-Induced Nausea and Vomiting (CINV): This is the main use of fosaprepitant. It’s particularly effective for preventing both acute (occurring within 24 hours) and delayed (occurring after 24 hours) nausea and vomiting associated with highly emetogenic (likely to cause vomiting) chemotherapy[1][4].
  • Post-Operative Nausea and Vomiting (PONV): Some studies have explored the use of fosaprepitant in preventing nausea and vomiting after surgery[5].
  • Nausea and Vomiting in Specific Cancer Treatments: Research has been conducted on the use of fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy[6] and in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy[1].

How is Fosaprepitant Administered?

Fosaprepitant is given as an intravenous (IV) injection. The typical dosage is 150 mg, administered over 20-30 minutes. It’s usually given about 30 minutes before the start of chemotherapy[4]. In some cases, it may be given on a weekly or triweekly basis, depending on the chemotherapy regimen and the patient’s needs[1].

Fosaprepitant is often used in combination with other anti-nausea medications, such as ondansetron (a 5-HT3 antagonist) and dexamethasone (a corticosteroid), to provide comprehensive prevention of nausea and vomiting[3].

Effectiveness of Fosaprepitant

Clinical trials have shown fosaprepitant to be effective in preventing chemotherapy-induced nausea and vomiting. In one study, fosaprepitant was found to be equivalent to a 3-day regimen of oral aprepitant for controlling both acute and delayed nausea and vomiting[2].

The effectiveness of fosaprepitant is often measured by the “complete response” rate, which is defined as no vomiting and no use of rescue medication. Studies have shown high complete response rates in patients receiving fosaprepitant, particularly when used in combination with other anti-nausea medications[4][6].

Potential Side Effects

Like all medications, fosaprepitant can cause side effects, although not everyone experiences them. Common side effects may include:

  • Fatigue
  • Diarrhea
  • Weakness
  • Indigestion
  • Headache
  • Hiccups

More serious side effects are rare but can include allergic reactions or infusion site reactions. It’s important to report any unusual symptoms to your healthcare provider[4].

Ongoing Research and Future Applications

Research on fosaprepitant is ongoing, with several studies exploring its use in different patient populations and conditions:

  • Pediatric Use: Studies are being conducted to determine appropriate dosing and effectiveness of fosaprepitant in children and adolescents[3].
  • Traumatic Brain Injury: Researchers are investigating whether fosaprepitant could help reduce brain swelling and intracranial pressure in patients with traumatic brain injuries[7].
  • Different Cancer Types: Studies are exploring the use of fosaprepitant in various cancer types and treatment regimens, including colorectal cancer, nasopharyngeal carcinoma, and high-dose interleukin-2 therapy for metastatic melanoma and renal cell carcinoma[6][1][8].

These ongoing studies may lead to new applications for fosaprepitant in the future, potentially benefiting a wider range of patients.

Study Focus Key Findings Patient Population
CINV in lung cancer Fosaprepitant improved complete response rates for nausea/vomiting control Advanced non-small cell lung cancer patients
CINV in melanoma/renal cancer Evaluated fosaprepitant efficacy with high-dose interleukin-2 therapy Metastatic melanoma and renal cell carcinoma patients
CINV in colorectal cancer Compared fosaprepitant to standard antiemetic therapy Colorectal cancer patients receiving oxaliplatin chemotherapy
CINV in nasopharyngeal cancer Compared weekly vs. triweekly fosaprepitant dosing Nasopharyngeal carcinoma patients undergoing chemoradiotherapy
PONV Compared fosaprepitant to palonosetron for PONV prevention Women undergoing laparoscopic cholecystectomy
Traumatic brain injury Evaluated fosaprepitant for reducing intracranial pressure Patients with severe traumatic brain injury

FAQ

  • What is fosaprepitant and how does it work? Fosaprepitant is an intravenous medication that works by blocking the neurokinin-1 receptor in the brain, which is known to cause nausea and vomiting. It is converted to the active form aprepitant in the body.
  • What conditions is fosaprepitant being studied for? Clinical trials are evaluating fosaprepitant for preventing and treating chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, and nausea/vomiting in other conditions like traumatic brain injury.
  • How is fosaprepitant typically administered in clinical trials? In most trials, fosaprepitant is given as a single intravenous dose of 150 mg, usually 30 minutes before chemotherapy or surgery. Some studies use multiple doses over several days.
  • What are the potential benefits of fosaprepitant over other antiemetics? Fosaprepitant may provide longer-lasting nausea and vomiting control compared to some other antiemetics. It also does not appear to cause QT prolongation, a potential side effect of some other antiemetic medications.
  • Are there any side effects associated with fosaprepitant in clinical trials? The most common side effects reported in trials include headache and fatigue. However, fosaprepitant appears to be generally well-tolerated in most patients studied so far.

Ongoing Clinical Trials on Fosaprepitant

  • Study on IV NEPA (Fosnetupitant/Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Poland Romania

  • Study of palonosetron and fosaprepitant to prevent nausea and vomiting after laparoscopic surgery

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on the Effectiveness of Aprepitant and Fosaprepitant in Preventing Nausea and Vomiting in Children Undergoing Chemotherapy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Antiemetic: A medication used to prevent or treat nausea and vomiting
  • Chemotherapy-induced nausea and vomiting (CINV): Nausea and vomiting that occurs as a side effect of cancer chemotherapy treatments
  • Neurokinin-1 (NK1) receptor: A receptor in the brain involved in triggering nausea and vomiting that is blocked by fosaprepitant
  • Postoperative nausea and vomiting (PONV): Nausea and vomiting that occurs after surgery, often as a side effect of anesthesia
  • QT prolongation: A heart rhythm problem that can be a side effect of some medications, potentially leading to abnormal heart rhythms
  • Randomized controlled trial: A type of clinical study where participants are randomly assigned to different treatment groups to compare outcomes
  • Visual analog scale (VAS): A measurement tool used to assess subjective experiences like nausea intensity on a continuous scale

References

  1. https://clinicaltrials.gov/study/NCT04636632
  2. https://clinicaltrials.gov/study/NCT02407600
  3. https://clinicaltrials.gov/study/NCT01697579
  4. https://clinicaltrials.gov/study/NCT05755659
  5. https://clinicaltrials.gov/study/NCT03586817
  6. https://clinicaltrials.gov/study/NCT01344304
  7. https://clinicaltrials.gov/study/NCT03035838
  8. https://clinicaltrials.gov/study/NCT01874119